Skip to main content

Table 1 Patient characteristics

From: Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

Characteristic

Everolimus 5 mg/day

(n = 12)

Everolimus 10 mg/day

(n = 12)

Median (range) age, y

55 (27-75)

56 (32-75)

Sex, n (%)

  

   Male

5 (41.7)

4 (33.3)

   Female

7 (58.3)

8 (66.7)

WHO performance status, n (%)

  

   0

3 (25.0)

1 (8.3)

   1

9 (75.0)

9 (75.0)

   2

0

2 (16.7)

Prior antineoplastic therapy, n (%)

  

   Surgery

11 (91.7)

10 (83.3)

   Radiotherapy

3 (25.0)

3 (25.0)

   Chemotherapy

10 (83.3)

10 (83.3)

   Targeted therapy

5 (41.7)

5 (41.7)

   Immunotherapy

3 (25.0)

2 (16.7)

   Hormonal therapy

2 (16.7)

0

  1. WHO = World Health Organization.